23
Jan
2020

Much Ado about Coronavirus and 23andMe Hits the Wall

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Lilly, Genentech Alzheimer’s Drugs Fail, Revolution’s Big IPO, & an Obesity Drug Disappears
Sanofi’s Intriguing MS Drug, Merck’s Big Spinoff & a New Peanut Allergy Drug
Wuhan Coronavirus Fear Spreads, CVS Feels the Heat & Black Diamond’s Sizzling IPO
Lilly’s Half-Measure on Insulin, Illumina’s Up-Market Play, & the Little Deals from SF